The ultra-long-acting dipeptidase IV (DPP-4) inhibitor trelogliptin, which is used in the treatment of type 2 diabetes, was approved for marketing in Japan in 2015. Trasagliptin is a new type II diabetes hypoglycemic drug developed by Takeda Corporation of Japan, which prevents the degradation of incretin through the inhibition of DPP-4, so that incretin plays a long-term role and maintains the blood sugar of diabetic people at normal values.
So, what is the efficacy of the world's first weekly hypoglycemic drug tresagliptin?
Trafiglitin is given once a week to effectively control blood glucose levels and improve patient adherence. The double-blind controlled trial targeted patients with type 2 diabetes who took trafiglistine 100 mg once a week before meals for 12 weeks. At the end of the treatment period, the average value (standard deviation) after correction of HbA1c (NGSP value) relative to the change value before administration was 0.35% in the placebo group and 0.54% in the trelogliptin 100 mg group. A significant decrease in HbA1c was observed in the traglittin 100 mg group relative to the placebo group. The mean (standard deviation) of HbA1c (NGSP value) before administration was 8.15 (0.95)in the placebo group, compared with 8.41 (0.97) in the tracagliptin 100 mg group.
So, what are the side effects of traglittine?
Intestinal obstruction, rash, itching, constipation, persistent abdominal pain, acute pancreatitis, atrial fibrillation, bloating, persistent severe abdominal pain, elevated lipase, vomiting, nasopharyngitis, etc. are more common side effects of tripratin, and patients need to take appropriate measures to deal with side effects according to their own reactions. If the patient develops intolerance during medication, the doctor should be contacted promptly for a new treatment regimen.
Note: The above information comes from the network, compiled and edited by medical companion travel (if there is any error, please help correct), only to provide information on the latest listed drugs in the world, to help Chinese patients understand the international new drug dynamics, only for internal discussion of medical staff, without any medication basis, specific medication guidelines, please consult the attending physician.